Lawrence WILKINSON

Dr. Lawrence WILKINSON


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
LWLawrence WILKINSON
Lawrence WILKINSON
WDWilliam Davies
William Davies
AIAnthony Isles
Anthony Isles

1 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Ana SilvaAna Silva
Ana Silva
JHJosephine E. Haddon
Josephine E. Haddon
YSYasir Ahmed Syed
Yasir Ahmed Syed
STSimon Trent
Simon Trent
TLTzu-Ching E. Lin
Tzu-Ching E. Lin
LWLawrence WILKINSON
Lawrence WILKINSON
The biological basis of the increased risk for psychiatric disorders seen in 15q11.2 copy number deletion is unknown. Previous work has shown disturbances in white matter tracts in human carriers of the deletion. Here, in a novel rat model, we recapitulated low dosage of the candidate risk geneCYFIP1present within the 15q11.2 interval. Using diffusion tensor imaging, we first showed extensive white matter changes inCyfip1mutant rats, which were most pronounced in the corpus callosum and external capsule. Transmission electron microscopy showed that these changes were associated with thinning of the myelin sheath in the corpus callosum. Myelin thinning was independent of changes in axon number or diameter but was associated with effects on mature oligodendrocytes, including aberrant intracellular distribution of myelin basic protein. Finally, we demonstrated effects on cognitive phenotypes sensitive to both disruptions in myelin and callosal circuitry.

8 December 2016 in Molecular Brain
Verified
Journal Article
Open access
PDF file
AGAlastair S. Garfield
Alastair S. Garfield
JDJennifer R. Davies
Jennifer R. Davies
LBLuke K. Burke
Luke K. Burke
HFHannah V. Furby
Hannah V. Furby
LWLawrence WILKINSON
Lawrence WILKINSON
AIAnthony Isles
Anthony Isles
Alternate splicing of serotonin (5-hydroxytryptamine; 5-HT) 2C receptor (5-HT2CR) pre-RNA is negatively regulated by the small nucleolar RNA, Snord115, loss of which is observed in nearly all individuals with Prader-Willi Syndrome (PWS), a multigenic disorder characterised by hyperphagia and obesity. Given the role of the 5-HT2CR in the regulation of ingestive behaviour we investigated the pathophysiological implications of Snord115 deficiency on 5-HT2CR regulated appetite in a genotypically relevant PWS mouse model (PWS-IC). Specifically, we demonstrate that loss of Snord115 expression is associated with increased levels of hypothalamic truncated 5-HT2CR pre-mRNA. The 5-HT2CR promotes appetite suppression via engagement of the central melanocortin system. Pro-opiomelancortin (Pomc) mRNA levels within the arcuate nucleus of the hypothalamus (ARC) were reduced in PWS-IC mice. We then went on to assess the functional consequences of these molecular changes, demonstrating that PWS-IC mice are unresponsive to an anorectic doses of a 5-HT2CR agonist and that this is associated with attenuated activation of POMC neurons within the ARC. These data provide new insight into the significance of Htr2c pre-mRNA processing to the physiological regulation of appetite and potentially the pathological manifestation of hyperphagia in PWS. Furthermore, these findings have translational relevance for individuals with PWS who may seek to control appetite with another 5-HT2CR agonist, the new obesity treatment lorcaserin.

9 May 2013 in Neuropsychopharmacology
Verified
Journal Article
Closed access
THTrevor Humby
Trevor Humby
JEJessica B Eddy
Jessica B Eddy
MGMark A Good
Mark A Good
ARAmy C Reichelt
Amy C Reichelt
LWLawrence WILKINSON
Lawrence WILKINSON

20 May 2007 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SLSarah L. Lambourne
Sarah L. Lambourne
THTrevor Humby
Trevor Humby
AIAnthony R. Isles
Anthony R. Isles
PEPiers C. Emson
Piers C. Emson
MSMaria G. Spillantini
Maria G. Spillantini
LWLawrence WILKINSON
Lawrence WILKINSON
Abnormalities in microtubule-associated tau protein are a key neuropathological feature of both Alzheimer's disease and many frontotemporal dementias (FTDs), including hereditary FTD with Parkinsonism linked to chromosome 17 (FTDP-17). In these disorders, tau becomes aberrantly phosphorylated, leading to the development of filamentous neurofibrillary tangles in the brain. Here we report, in a longitudinal ageing study, the sensorimotor and cognitive assessment of transgenic mice expressing the human tau V337M (‘Seattle Family A’) FTDP-17 mutation, which we have previously shown to demonstrate abnormalities in brain tau phosphorylation. The data indicated highly specific effects of transgene expression on the ability to withhold responding in a murine version of the 5-choice serial reaction time task, behaviour consistent with deficits in impulse control. Ageing exacerbated these effects. In young tau V337M mice, increased impulsivity was present under task conditions making inhibition of premature responding more difficult (longer inter-trial intervals) but not under baseline conditions. However, when older, the tau V337M mice showed further increases in premature responding, including under baseline conditions. These impulse control deficits were fully dissociable from sensorimotor or motivation effects on performance. The findings recapitulate core abnormalities in impulsive responding observed in both frontal variant FTD and FTDP-17 linked to the tau V337M mutation in humans.

20 May 2014 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
WDWilliam Davies
William Davies
THTrevor Humby
Trevor Humby
STSimon Trent
Simon Trent
JEJessica B Eddy
Jessica B Eddy
OOObah A Ojarikre
Obah A Ojarikre
LWLawrence WILKINSON
Lawrence WILKINSON
Maladaptive response control is a feature of many neuropsychiatric conditions, including attention deficit hyperactivity disorder (ADHD). As ADHD is more commonly diagnosed in males than females, a pathogenic role for sex-linked genes has been suggested. Deletion or point mutation of the X-linked STS gene, encoding the enzyme steroid sulfatase (STS) influences risk for ADHD. We examined whether deletion of the Sts gene in the 39,XY*O mouse model, or pharmacological manipulation of the STS axis, via administration of the enzyme substrate dehydroepiandrosterone sulfate or the enzyme inhibitor COUMATE, influenced behavior in a novel murine analog of the stop-signal reaction time task used to detect inhibitory deficits in individuals with ADHD. Unexpectedly, both the genetic and pharmacological treatments resulted in enhanced response control, manifest as highly specific effects in the ability to cancel a prepotent action. For all three manipulations, the effect size was comparable to that seen with the commonly used ADHD therapeutics methylphenidate and atomoxetine. Hence, converging genetic and pharmacological evidence indicates that the STS axis is involved in inhibitory processes and can be manipulated to give rise to improvements in response control. While the precise neurobiological mechanism(s) underlying the effects remain to be established, there is the potential for exploiting this pathway in the treatment of disorders where failures in behavioral inhibition are prominent.